GURUFOCUS.COM » STOCK LIST » USA » NYSE » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Debt-to-EBITDA
Switch to:

Myovant Sciences Debt-to-EBITDA

: -11.37 (As of Jun. 2022)
View and export this data going back to 2016. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Myovant Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $2.3 Mil. Myovant Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $365.1 Mil. Myovant Sciences's annualized EBITDA for the quarter that ended in Jun. 2022 was $-32.3 Mil. Myovant Sciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was -11.37.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Myovant Sciences's Debt-to-EBITDA or its related term are showing as below:

MYOV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2   Med: -0.46   Max: -0.31
Current: -2.71

During the past 7 years, the highest Debt-to-EBITDA Ratio of Myovant Sciences was -0.31. The lowest was -2.00. And the median was -0.46.

MYOV's Debt-to-EBITDA is ranked worse than
100% of 300 companies
in the Biotechnology industry
Industry Median: 0.90 vs MYOV: -2.71

Myovant Sciences Debt-to-EBITDA Historical Data

The historical data trend for Myovant Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Debt-to-EBITDA
Premium Member Only Premium Member Only -0.31 -0.38 -0.46 -1.53 -2.00

Myovant Sciences Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.63 -5.29 -1.56 -1.80 -11.37

Competitive Comparison

For the Biotechnology subindustry, Myovant Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Myovant Sciences Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Debt-to-EBITDA falls into.



Myovant Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Myovant Sciences's Debt-to-EBITDA for the fiscal year that ended in Mar. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.148 + 365.741) / -183.89
=-2.00

Myovant Sciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.256 + 365.131) / -32.32
=-11.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.


Myovant Sciences  (NYSE:MYOV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Myovant Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences Business Description

Myovant Sciences logo
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Valente Nancy director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Mehra Uneek officer: Principal Financial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Merendino Lauren officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Marek David C director, officer: Principal Executive Officer C/O WEBMD HEALTH CORP. 111 EIGHTH AVENUE NEW YORK NY 10011
Nomura Hiroshi director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME CHUO-KU TOKYO M0 103-6020
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 60 WALL STREET NEW YORK NY 10005
Gulfo Adele M. director ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Lo Andrew 10 percent owner C/O ALPHASIMPLEX GROUP, LLC ONE CAMBRIDGE CENTER, 9TH FLOOR CAMBRIDGE MA 02142
Viking Global Equities Master Ltd. 10 percent owner 55 RAILROAD AVENUE GREENWICH CT 06830
Sablich Kim officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Torti Frank director 2855 SAND HILL ROAD MENLO PARK CA 94025
Potter Myrtle S director 10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark director C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094

Myovant Sciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)